Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.30
-0.9%
$39.76
$31.72
$45.59
$88.10B0.535.85 million shs13.11 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.30
-0.9%
$39.76
$31.72
$45.59
$88.10B0.535.85 million shs13.11 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shs40 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.37
+1.1%
$24.67
$20.92
$30.43
$155.59B0.5562.00 million shs70.44 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+8.72%+7.16%+13.33%+11.55%
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+8.72%+7.16%+13.33%+11.55%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+15.22%+10.10%+8.46%-4.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.30
-0.9%
$39.76
$31.72
$45.59
$88.10B0.535.85 million shs13.11 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.30
-0.9%
$39.76
$31.72
$45.59
$88.10B0.535.85 million shs13.11 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shs40 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.37
+1.1%
$24.67
$20.92
$30.43
$155.59B0.5562.00 million shs70.44 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+8.72%+7.16%+13.33%+11.55%
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+8.72%+7.16%+13.33%+11.55%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+15.22%+10.10%+8.46%-4.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.88
Reduce$37.38-13.69% Downside
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.88
Reduce$37.38-13.69% Downside
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.413.83% Upside

Current Analyst Ratings Breakdown

Latest IMGN, GSK, GSK, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$25.00 ➝ $26.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$32.00 ➝ $33.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$27.00 ➝ $28.00
(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B2.20$5.57 per share7.77$8.07 per share5.37
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B2.20$5.57 per share7.77$8.07 per share5.37
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
Pfizer Inc. stock logo
PFE
Pfizer
$63.83B2.44$4.36 per share6.27$15.62 per share1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$2.1620.059.311.9410.81%49.22%11.31%10/29/2025 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$2.1620.059.311.9410.81%49.22%11.31%10/29/2025 (Estimated)
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8814.569.030.8816.84%21.42%9.12%11/4/2025 (Estimated)

Latest IMGN, GSK, GSK, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2025Q3 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.22N/AN/AN/A$8.21 billionN/A
10/29/2025Q3 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.22N/AN/AN/A$8.21 billionN/A
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.683.88%N/A77.78%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.683.88%N/A77.78%N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.29%N/A91.49%16 Years

Latest IMGN, GSK, GSK, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.07
0.87
0.57
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.07
0.87
0.57
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.03 billion1.83 billionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.03 billion1.83 billionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

3 Reasons to Buy Pfizer Stock Now
Pfizer – TrumpRx deal boosts Big Pharma to a record rally
Can Pfizer's Stock Break This Disappointing Streak?
Can Pfizer's Stock Break This Disappointing Streak?
OLD National Bancorp IN Boosts Holdings in Pfizer Inc. $PFE
Talbot Financial LLC Increases Stake in Pfizer Inc. $PFE
Clarius Group LLC Purchases 21,661 Shares of Pfizer Inc. $PFE
111 Capital Decreases Stake in Pfizer Inc. $PFE
Bank of America Securities Maintains Buy on Pfizer Inc (PFE)
Pfizer (NYSE:PFE) Price Target Raised to $30.00 at Bank of America
Demystifying Pfizer: Insights From 4 Analyst Reviews

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GSK stock logo

GSK NYSE:GSK

$43.30 -0.39 (-0.89%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$43.60 +0.30 (+0.68%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$43.30 -0.39 (-0.89%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$43.60 +0.30 (+0.68%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Pfizer stock logo

Pfizer NYSE:PFE

$27.36 +0.29 (+1.05%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$27.45 +0.09 (+0.31%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.